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ABSTRACT
Background: Chronic non-malignant lung diseases such as chronic obstructive pulmonary dis-
ease (COPD) and interstitial lung diseases (ILD) result in reduced quality of life (QoL), a high
symptom burden and reduced survival. Patients with chronic non-malignant lung disease often
have limited access to palliative care. The symptom burden and the QoL of these patients
resembles patients with cancer and the general palliative approach is similar. However, the
disease trajectory is often slow and unpredictable, and the palliative effort must be built on
accessibility, continuity and professional competences. The Danish Health Authority as well as the
WHO recommends that there is access to palliative care for all patients with life-threatening
diseases regardless of diagnosis. In 2011, the Danish Health Authority requested that the national
medical societies would to formulate guidelines for palliation.
Methods: In 2015, a group of members of the Danish Respiratory Society (DRS) was appointed for
this purpose. It was composed of experienced ILD and COPD researchers as well as clinicians from
different parts of Denmark. A literature review was made, a draft was prepared, and all recom-
mendations were agreed upon unanimously.
Results: The Danish version of the position paper was finally submitted for review and accepted
by all members of DRS.
Conclusion: In this position paper we provide recommendations on the terminology of chronic
and terminal lung failure, rehabilitation and palliative care, advanced care planning, informal
caregivers and bereavement, symptom management, the imminently dying patient, and organi-
zation of palliative care for patients with chronic non-malignant lung diseases.
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Background
The World Health Organization (WHO) has defined
palliative care as ‘ an approach that improves the quality
of life of patients and their families facing the problem
associated with life-threatening illness, through the preven-
tion and relief of suffering by means of early identification
and impeccable assessment and treatment of pain and
other problems, physical, psychosocial and spiritual [1]’.
Palliative care in patients withmalignant lung diseases is
well established and validated [2], but there is a knowledge
gap concerning palliation in patients with chronic non-
malignant lung diseases and their access to palliative care
[3,4]. Chronic obstructive pulmonary disease (COPD) and
interstitial lung diseases (ILD) may differ from cancer with
respect to pathophysiology and prognosis, but in general
palliative care practices remain similar. The treatment goals
for all progressive lung diseases are to alleviate symptoms,
to slow down disease progression and thereby improve
QOL. These goals are best achieved in a collaboration
between the informed, active patient, the primary care-
giver(s) and a well-prepared pro-active multidisciplinary
team [5,6].
It is a common misconception that palliation should
only be initiated in the terminal phase of a disease.
Palliation should be initiated early in the course of the
disease alongside disease-specific treatment, and should
aim at easing the disease burden when QOL is reduced
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[7–14]. The hallmark of chronic non-malignant lung
disease is its unpredictable course, the considerable
uncertainty that may result in prognostic paralysis [15]
as well as delay in conversations between the patient and
health care professionals regarding end-of-life issues,
often due to a fear of addressing these topics too early.
The Danish Health Authority has called for national
guidelines for palliative care in non-malignant chronic,
progressive, symptomatic diseases [14]. A task force
was appointed by the Danish Respiratory Society
(DRS), and the present position paper describes the
recommendations of the task force [16].
Methods
In 2015, DRS appointed a group of members including
experienced COPD and ILD researchers as well as
clinicians from different parts of Denmark.
A literature review was conducted and new litera-
ture searches were repeatedly updated with new or
expanded search criteria. Thus, the current document
is a position paper and not a systematic review.
A draft was prepared, and several meetings were
held to clarify form and definitions. A primary author
wrote the first draft that went through several reviews
in the appointed DRS group; all definitions and recom-
mendations were agreed upon unanimously. The posi-
tion paper was finally submitted for review and
accepted by all members of DRS. The Danish version
is published on the DRS website (https://www.lungeme
dicin.dk/fagligt/klaringsrapporter.html).
Terminology
When treating patients with life-threatening diseases, it
is important to have a well-defined terminology.
Therefore, DRS began by defining the three stages of
disease where palliative care should be considered.
Chronic lung failure
Chronic lung failure is defined as a permanently
reduced lung function and presence of daily symptoms
despite optimal standard treatment. Chronic lung fail-
ure is present when the disease limits activities of daily
living.
Patients may develop chronic lung failure due to
different diseases such as COPD, ILD or bronchiecta-
sis. In patients with chronic lung failure, the disease is
so severe that palliative care, as described in this docu-
ment, can be initiated. In patients with chronic lung
failure prognostication may thus be difficult and the
definition does not rely on expected time to death.
Terminal lung failure
Terminal lung failure is when death is anticipated to be
close. There are no validated clinical tools for assessing
the short-time risk of death within for instance 6
months. DRS recommends using the following criteria:
Chronic obstructive pulmonary disease (COPD)
The patient is considered to be in the terminal phase of
the disease when dependent on help from others
because of dyspnea or general weakness over a period
of several months, and when at least two of the follow-
ing criteria are fulfilled:
• At least two hospitalizations because of a COPD
exacerbation and/or one hospitalization requiring
treatment with non-invasive ventilation (NIV) or a
ventilator within the past 6 months.
• Need of long-term oxygen therapy (LTOT)
• Permanent NIV treatment at home
• Bodymass index (BMI) <18 despite optimal nutrition,
including nutritional supplementation
• Progressive or newly diagnosed severe comorbidity
Interstitial lung diseases (ILD)
The patient is considered to be in the terminal phase of
the disease when dependent on help from others
because of dyspnea or general weakness over a period
of several months, and when fulfilling at least two of
the following criteria:
• Two or more respiratory hospitalizations (e.g., due
to infection or exacerbation) within the last year
• Peripheral oxygen saturation <88% at rest
• Reduced physical activity level (6-minute walk
distance <212 m)
• Pulmonary hypertension
• Forced vital capacity (FVC) <50% of predicted or %
FVC decline >10% of predicted or % predicted diffusion
capacity for carbon monoxide (DLCO) decline >15% of
predicted during the last 6 months
• Progressive or newly diagnosed severe comorbidity
Recommendation 1. Terminology
Chronic lung failure is defined as a permanently reduced lung
function and daily symptoms limiting daily activities despite optimal
standard therapy. Palliative care can be started at this point.
Terminal lung failure is present when a patient with chronic lung
failure meets the criteria of being terminally ill and when life
expectancy is limited to weeks or a few months.
Imminently dying is when death is expected shortly i.e. within hours
or a few days
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The life expectancy of patients with terminal lung
disease is anticipated to span fromweeks to a fewmonths.
The imminently dying patient
The patient is imminently dying when the disease has
progressed to a stage where only symptomatic treat-
ment is warranted. All other treatment possibilities are
futile, and death is expected within hours or few days.
Rehabilitation and palliative care
The American Thoracic Society (ATS)/European
Respiratory Society (ERS) definition of pulmonary rehabi-
litation: ‘Pulmonary rehabilitation is a comprehensive inter-
vention based on a thorough patient assessment followed by
patient-tailored therapies that include, but are not limited to,
exercise training, education, and behavior change, designed
to improve the physical and psychological condition of people
with chronic respiratory disease and to promote the long-
term adherence to health-enhancing behaviors [17].’
Pulmonary rehabilitation is a multidisciplinary
effort aiming at, but not limited to, improving the
physical function, nutrition, knowledge of the disease
and change towards a more healthy and active lifestyle
for the individual patient. Pulmonary rehabilitation is
designed to improve both the physical and psychologi-
cal state and to promote a continued health behavior
change [18,19].
Ideally, palliation and rehabilitation are based on a
comprehensive assessment of the needs and wishes of the
individual patient and caregiver. Rehabilitation is an
important component of palliative care and should be
tailored to meet the individual patient’s needs. Some
patients may need exercise programs to increase their
physical capacity, while others may aim to reduce their
decline in physical function and their need for continuous
training and support. The concept of personalizedmanage-
ment is a combination of rehabilitation and palliative care
(Figure 1).
Rehabilitation is expected to result in improved
symptom control and functional capacity, and thus
improved overall QOL [20]. Rehabilitation should be
offered to all patients with symptomatic chronic lung
diseases, even to those in the terminal phase of the
disease [18].
Definition
Advance care planning (ACP) is not a well-defined
concept in the international literature. Therefore, DRS
started by making a Danish guide [21] for ACP. The
DRS defines ACP as: A communication process between
the patient, the informal caregiver and the multidisci-
plinary team where focus is on living with a disease and
symptoms. In this process issues like treatment limita-
tions including end-of-life decisions can be discussed;
however, ACP should not be limited to these topics.
There is no evidence that clearly defines the optimal
timing of ACP; however, it is agreed that ACP should
preferably be performed in a clinically stable phase of
disease and not during hospitalization due to e.g. an
acute exacerbation [22]. An important aspect of the ACP
is to involve both the formal and informal caregivers [23].
It is recommended to allocate sufficient time for
ACP conversation, as these are typically more time
consuming than routine follow-up visits [24]. A
Danish pilot study showed that ACP in patients with
COPD lasted from 28 to 47 min and for up to 112 min
in other diseases [25].
It must be kept in mind that ACP is not a checklist,
but is intended to increase the understanding of the
individual patient’s values and choices and to provide a
better understanding of the disease for both the patient
and the caregiver(s) [26,27]. The goal of ACP is not
necessarily to reduce or stop treatment, but to ensure a
balanced treatment based on an understanding of the
needs and wishes of the individual patient.
Communication
During routine follow-up visits, health care providers
do not always gain insight into what the patients per-
ceive as their most troublesome symptoms [28,29].
Detailed knowledge of symptoms and disease burden
is a prerequisite for targeted treatment and symptom
relief. As in all patients with chronic diseases, commu-
nication is crucial for treatment adherence and lack of
a common understanding of the disease, symptoms
and treatment can hamper the benefits of palliation.
Recommendation 2. Rehabilitation and palliative care
Palliation and pulmonary rehabilitation aim to improve the ability of
patients and caregivers to live an active life according to their individual
values despite their chronic lung disease.
Patients and caregivers should be involved in the design of an
individualized treatment plan.
Recommendation 3. Advance care planning (ACP)
ACP is one or preferably several conversations where the patient, the
multidisciplinary team and the informal caregiver discuss realistic
treatment goals and the patient’s perceptions of living with the
disease.
Communication is the key in active management of patients with
chronic lung failure.
All patients with chronic lung failure should be offered ACP
conversations once a year. ACP topics should focus on the patient’s
needs and wishes and should never develop into a checklist.
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Bereaved caregivers
A chronic disease affects not only the patient but also
the caregiver(s). The feeling of being able to help a
loved one is called caregiver benefits. However, living
with a loved one who suffers from an increasingly
symptomatic disease can be stressful; this is called the
caregiver burden. Comparative studies have shown that
it is not the underlying disease that determines the
burden of disease on informal caregivers, but rather
the psychosocial resources of the caregiver [30]. If the
informal caregivers perceive themselves as sick or as
economically poor, the feeling of the caregiver burden
is increased [31].
It is therefore important to improve the ability of
caregivers to cope and live with serious illness in the
close family [32]. The active involvement of caregivers
in pulmonary rehabilitation has been shown to result
in improved coping strategies in patients and families
and in psychosocial well-being [33]. It is common that
the needs for information among caregivers and
patients are not similar, and ACP can be one way to
address this [34] and optimize communication between
patient and caregiver(s) [34].
Dyspnea
Dyspnea is the patient’s perception of shortness of
breath or air hunger. The perception of dyspnea is
complex and depends on a variety of somatic and
psychological factors such as deconditioning, under-
weight, anxiety, depression and other comorbidities
such as cardiac disease [35]. Dyspnea is closely related
to QOL and treatment and relief of dyspnea is of major
importance. In pain management, the concept of ‘total
pain’ describes the physical, mental, social, cultural and
spiritual component of pain sensation. This broad
understanding of ‘total dyspnea’ should be used in
patients with chronic lung disease [36,37].
In addition to the pharmacological treatment of dys-
pnea, patient education, relaxation, breathing techni-
ques and exercises are helpful [38,39]. Dyspnea may
result in decreased physical activity and thus an inactive
lifestyle, resulting in loss of muscle mass and decondi-
tioning, which may further worsen dyspnea [40].
Physical rehabilitation is therefore an important way to
improve dyspnea.
Figure 1. Personalized management and palliation includes symptom treatment, rehabilitation, patient education and support. Palliative
support, including psychological, social and existential support, may continue into care for the informal caregiver after the patient’s death.
Routine and early Advance Care Planning (ACP) provide the ability to adjust treatment goals during the disease trajectory.
Recommendation 4. Informal caregivers and bereavement
Severe disease affects not only the patient but also the informal
caregiver(s), who should be offered to participate in ACP,
rehabilitation, education and a follow-up after the patient’s death.
Recommendation 5. Symptom management
Patients should be advised on and assisted in obtaining a lifestyle that
helps to reduce the symptom burden.
Comorbidities should be diagnosed and treated.
Dyspnea and dyspnea-related anxiety may be difficult to separate and
should be treated as a single symptom.
Malnutrition is a marker of disease severity and must lead to special
dietary advice.
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Dyspnea-related anxiety and depression
Dyspnea is terrifying for most patients and anxiety may
worsen the situation. Dyspnea and dyspnea-related
anxiety are difficult to distinguish and should therefore
be considered as a single symptom. Anxiety in patients
with COPD increases the risk of hospitalization and
results in a self-reinforcing relationship [41,42]. In
some patients, anxiety is seen as a direct part of the
underlying disease and is therefore perceived as a mar-
ker of disease severity rather than a co-morbidity [42].
Opioids
There is a general consensus on the benefits of low-dose
opioids to relieve dyspnea. This is supported by some
evidence in COPD, while the evidence in ILD is limited
[10,36,43–46]. When opioids are used, it is recommended
to start with a low dose of morphine and to increase the
dose slowly. Doses of 2.5 to 5mgof oralmorphine are often
used as an initial dose, slowly increased until a beneficial
effect is achieved. Opioid doses of up to 30 mg daily have
not been associated with an increased rate of hospitaliza-
tion or mortality in COPD, regardless of hypercapnia [47].
A small study on patients with IPF suggested the benefit of
a single dose to relieve dyspnea without oxygen desatura-
tion [48].
Benzodiazepines
Benzodiazepine treatment in COPD may be associated
with a slightly increased mortality [47,49,50] and its
effect on the perception of dyspnea is not fully eluci-
dated [11,38,43]. Benzodiazepines reduce anxiety and
can be tried when anxiety is a major component [11,50].
Corticosteroids
Low-dose prednisolone of 5–10mgdaily is sometimes used
to relieve dyspnea. Corticosteroids have a beneficial effect
on fatigue, but also significant side effects. There is a dose-
effect relationship between adverse events but even at low
doses, physical adverse events such as weight gain, gastro-
intestinal bleeding, osteoporosis, glaucoma, hypertension,
increased risk of diabetes [51], and psychological side
effects such as delirium, confusion, depression and mania
have been observed [52]Corticosteroids may in selected
cases be helpful to stabilize and increase wellbeing and
appetite, but the risk of long-term adverse events should
be balanced against disease severity and life expectancy.
Long-term oxygen treatment (LTOT)
LTOT may be a necessary and life-prolonging treatment
in COPD and pulmonary fibrosis. However, LTOT may
result in immobilization and dry out the mucous mem-
branes, whichmay outweigh the benefits in somepatients.
In normoxic patients, it is questionable whether oxygen
relieves dyspnea and it is therefore only prescribed as
palliation after careful individual assessment [38].
Cough
Persistent cough is common in patients with COPDor ILD
[53]. Patients should be evaluated and treated for under-
lying causes such as reflux or sinusitis. Moreover, attention
should be paid to side effects fromother drugs such as ACE
inhibitors. In COPD, use of inhalers and inhalation med-
ications should be optimized.
When no other cause for cough is found, low dose
opioids can be tried. However, the scientific evidence is
limited [53,54]. There is a growing interest in chronic
cough and its similarity to neuropathic pain; gabapen-
tin has been shown to improve the condition at accep-
table side effects [55–57].
Malnutrition
Malnutrition and particularly loss ofmusclemass is related
to poor survival in COPD. While underweight is a bad
prognostic sign, the same has not been shown for over-
weight. The relationship between obesity, the worsening of
comorbidities and the symptom burden is poorly investi-
gated [58]. Recent studies suggest that nutrition therapy
may improve the condition of severely underweight
patients, particularly in combination with a rehabilitation
program [58–60].
No reliable or definite prognostic signs can define
when a patient is imminently dying. The assessment
is based on thorough knowledge of
(1) The patient’s overall disease burden, comorbid-
ities and potentially reversible acute conditions.
(2) Daily physical activities prior to hospitalization
Recommendation 6. Imminently dying patients with lung disease
The presence of ‘Imminently dying’ is based on a clinical assessment of
the patient’s current situation, comorbidity status, and the patient’s
personal wishes.
Treatment of the imminently dying patient focuses solely on symptom
treatment and relief.
Communication with the imminently dying patients and their
caregivers requires sufficient time, an appropriate environment and an
empathetic disclosure of the information.
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Restrictions in treatment and discontinuation
of treatment
Limitation of treatment covers the considerations on
treatment such as transfer to an intensive care unit,
non-invasive ventilation, ventilator therapy, or resusci-
tation in the case of cardiac arrest.
Central to the communication on treatment limitations
is the description and explanation of the underlying med-
ical reasons. Communication about limitations of treat-
ment should always be disclosed with empathy and
respect for the patient and caregivers.
When a patient is imminently dying, the treatment
should be appropriately adjusted. It is important to
regularly inform the patient and informal caregivers
about changes in treatment goals i.e. from disease
modifying treatment to symptom relief.
If the patient is awake, oxygen therapy can be
adjusted in accordance with the patient’s perception
of dyspnea. Oxygen dries out the mucous membranes
and is therefore only indicated in the imminently dying
patient to relieve dyspnea.
Fluid therapy and nutrition should be stopped after
thoroughly informing the patient and informal caregivers.
In the imminently dying patient, it may be difficult to
distinguish between anxiety, dyspnea or other disorders;
opioids and also benzodiazepines may be helpful.
Communication about death with the dying
patient and informal caregivers
Communication about death with the dying patient
and the informal caregivers requires communicative
skills and empathy. Conversations about these topics
should be allowed sufficient time [24]. The need for
information to both patient and caregivers is often
underestimated by health professionals [54].
Caregivers may have difficulties realizing the severity
of an exacerbation when their loved one has previously
survived other exacerbations. In such cases, it may be
helpful to discuss the daily activity and worsening over
time before the actual hospitalization to allow the care-
givers to formulate and accept that the patient’s under-
lying chronic lung disease has progressed and is worse
than before.
Case manager
The goal of a case manager model is not to reduce the
number of contacts to the health care system but to
improve the patient’s feeling of security, to reduce anxiety
and if possible also to reduce acute hospitalizations. A case
managermodel requires highly trained casemanagers, easy
accessibility and frequent contacts between the patient and
health care professionals [6,61].
Symptom screening
An understanding of patients symptoms and needs is
central to palliation and rehabilitation. Several validated
questionnaires exist. In patients with COPD, we recom-
mend use of theCOPDAssessment Test (CAT). TheCAT
consists of eight questions covering the most common
COPD symptoms. CAT is validated and correlates with
the St. George’s Respiratory Questionnaire (SGRQ) [62].
CAT can also be used in patients with ILD.
Multidisciplinary team
The key participants in the pulmonary palliative team are
physicians and nurses specialized in pulmonary medi-
cine. Other relevant participants may include general
practitioners, physiotherapists, palliative care specialists,
occupational therapists, dieticians, psychologists, hospital
chaplains and social workers.
The symptomatic, severely ill patient often consults
different specialists. A multidisciplinary team should in
addition to taking care of the patient, also coordinate
those involved in treatment and care provision. Positive
results with multidisciplinary team conferences within
existing budgets have been reported in England [63].
Telemedicine
There is considerable political interest and optimism about
the field of telemedicine, although evidence of the effect is
stillmodest [64].Obviously, the digitalization of our society
will result in changes in future communication forms.
Introduction of telemonitoring itself does not necessarily
improve QOL or reduce the number of hospitalizations
[65–67]. If introduced, it is important to adjust the tele-
intervention to fit the patient’s needs and technical skills
[66]. Telemedicine might be able to improve communica-
tion between health care providers and patients with severe
dyspnea and reduce the need for physically attending
appointments in the out-patient clinic.
Recommendation 7. Organization
Palliative care in respiratory diseases should be organized as a
multidisciplinary team approach.
The case manager’s objective is to ensure intensified, personalized
support for patients with severe and complex needs.
A symptom screening tool may be helpful to obtain the best possible
understanding of the overall symptomatology.
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Overall approach
Studies have shown that patients’ behavior can be changed
by a casemanager, patient education and self-management
plans. In COPD, this approach has in some studies resulted
in reduced healthcare costs [68], a lower rate of hospitaliza-
tiondue toCOPDexacerbations aswell as for other reasons
[69]. In contrast, other well-designed studies have found
excess mortality in self-help plan groups [70] and no effect
of nurse-controlled interventions [71]. These contradictory
results illustrate the complexity of severe chronic lung
disease and highlight the need for personalized
management.
There is limited knowledge of the optimal organization
of a comprehensive palliative care program for patients
with non-malignant chronic lung disease. Education and
training in palliative care should be a part of the pulmo-
nology training programs for both physicians and nurses.
Conclusion
Palliative care is based on a shared understanding of the
individual patient’s symptoms, needs, fears and hopes. It
is recommended to offer annual ACP conversations with
the patient and, if possible, the caregivers. When amutual
understanding is achieved and a plan is formulated, the
multidisciplinary team should start treatment according
to the identified needs and resources.
Early palliation allows for better systematization of the
different treatment needs, and for the development of a
long-term strategy.
The goal of palliative care is to support the patient and
caregivers to improve QOL throughout the disease
trajectory.
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